Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptor

Immune checkpoint inhibitors (antibodies that block the T cell co‐inhibitory receptors PD‐1/PD‐L1 or CTLA‐4) have revolutionized the treatment of some forms of cancer. Importantly, combination approaches using drugs that target both pathways have been shown to boost the efficacy of such treatments....

Descripción completa

Detalles Bibliográficos
Autores principales: MacLachlan, Bruce J., Mason, Georgina H., Greenshields‐Watson, Alexander, Triebel, Frederic, Gallimore, Awen, Cole, David K., Godkin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Molecular immunology and signaling
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101287/
https://www.ncbi.nlm.nih.gov/pubmed/32920841
http://dx.doi.org/10.1002/eji.202048753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101287/
https://www.ncbi.nlm.nih.gov/pubmed/32920841
http://dx.doi.org/10.1002/eji.202048753

Ejemplares similares